Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 17, 2012
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset...
-
Dec 7, 2012
Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer...
-
Nov 28, 2012
Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast...
-
Nov 12, 2012
Morphotek(® )Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug...
-
Oct 4, 2012H3 Biomedicine is first partner for program aimed at generating 'first-in-class' patient-relevant targets based on synthetic lethality screens
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines,...